Physician profile
Claire Lyons
NPI 1700567617
$1,410.34
in general payments reported to CMS, 2019-2025
18 companies · $1,257 in 2025
The $1,257 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $154 · 2025: $1,257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,318 · Education: $91.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,318.43 |
| Education | $91.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $259.33 | 2024-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $239.91 | 2025 | Fasenra, Breztri, Tezspire |
| Grifols USA, LLC | $119.82 | 2024-2025 | Xembify, Prolastin-C Liquid |
| Pharming Healthcare, INC. | $107.67 | 2024-2025 | Ruconest |
| Genentech USA, INC. | $98.33 | 2025 | Xolair |
| Genzyme Corporation | $94.55 | 2025 | |
| Biocryst US Sales Co., LLC | $83.30 | 2025 | Orladeyo |
| Amgen INC. | $80.77 | 2024-2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $77.73 | 2025 | |
| Lilly USA, LLC | $53.39 | 2025 | Ebglyss |
| Csl Behring | $34.44 | 2025 | Hizentra |
| Takeda Pharmaceuticals U.S.A., INC. | $29.70 | 2025 | Takhzyro |
| Optinose US, INC. | $29.54 | 2025 | |
| Baxter Healthcare | $25.69 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Verona Pharma, INC. | $24.37 | 2025 | Ohtuvayre |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $20.63 | 2025 | Neffy |
| Glaxosmithkline, LLC. | $15.87 | 2025 | Nucala |
| Cycle Pharmaceuticals INC | $15.30 | 2025 | Sajazir |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claire Lyons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.